NextCure acquires global rights to CDH6 ADC SIM0505; Q2 net loss $26.8M

NextCure, Inc.

Strategic partnership with Simcere Zaiming for SIM0505 (CDH6 ADC); NextCure holds rights ex-China.
First US patient dosing for SIM0505 expected in Q3 2025; Phase 1 data in China showed partial response.
LNCB74 (B7-H4 ADC) Phase 1 in cohort 4; backfill cohorts planned H2 2025.
Cash $35.3M as of June 30, 2025; expects to fund operations into mid-2026.
Simcere Zaiming made $2M equity investment; regained Nasdaq minimum bid price compliance.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.